| Literature DB >> 23318382 |
Maria Mamalui-Hunter1, Sridhar Yaddanapudi, Tianyu Zhao, Sasa Mutic, Daniel A Low, Robert E Drzymala.
Abstract
One of the most important aspects of quality assurance (QA) in radiation therapy is redundancy of patient treatment dose calculation. This work is focused on the patient-specific time and 3D dose treatment plan verification for stereotactic radiosurgery using Leksell Gamma Knife Perfexion (LGK PFX). The virtual model of LGK PFX was developed in MATLAB, based on the physical dimensions provided by the manufacturer. The ring-specific linear attenuation coefficients (LAC) and output factors (OFs) reported by the manufacturer were replaced by the measurement-based collimator size-specific OFs and a single LAC = 0.0065 mm-1. Calculation depths for each LGK PFX shot were obtained by ray-tracing technique, and the dose calculation formalism was similar to the one used by GammaPlan treatment planning software versions 8 and 9. The architecture of the QA process was based on the in-house online database search of the LGK PFX database search for plan-specific information. A series of QA phantom plans was examined to verify geometric and dosimetric accuracy of the software. The accuracy of the QA process was further evaluated through evaluation of a series of patient plans. The shot time/focus point dose verification for each shot took less than 1 sec/shot with full 3D isodose verification taking about 30 sec/shot on a desktop PC. GammaPlan database access time took less than 0.05 sec. The geometric accuracy (location of the point of maximum dose) of the phantom and patient plan was dependent on the resolution of the original dose matrix and was of the order of 1 dose element. Dosimetric accuracy of the independently calculated phantom and patient point (focus) doses was within 3.5% from the GammaPlan, with the mean = 2.3% and SD= 1.1%. The process for independent pretreatment patient-specific Gamma Knife Perfexion time and dose verification was created and validated.Entities:
Mesh:
Year: 2013 PMID: 23318382 PMCID: PMC5713665 DOI: 10.1120/jacmp.v14i1.3949
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Figure 1Ray‐tracing in case of gamma angle 70° (a) (cyan dots: points of beam surface entry); dose calculation geometry (b): Rs, gR, and Rp are radius vectors of an arbitrary Co‐60 source, the beam entry point along the skull surface and the arbitrary calculation point P, respectively. OAD is the effective off‐axis distance used for the off‐axis beam profile scaling. The angle α between the beam axis and the source‐to‐point P line is shown.
Figure 2Workflow (a) of the Gamma Knife patient information; steps (b) of the plan verification process.
Representative summary of the clinical use of the GPVT.
|
|
|
|
|
|---|---|---|---|
| Patient 1 | Multiple Metastasis | 11 | 20.99 |
| Patient 1 | Multiple Metastasis | 1 | 2.04 |
| Patient 1 | Multiple Metastasis | 5 | 9.59 |
| Patient 2 | Multiple Metastasis | 4 | 7.93 |
| Patient 2 | Multiple Metastasis | 3 | 5.83 |
| Patient 3 | Multiple Metastasis | 2 | 4.02 |
| Patient 4 | Trigeminal Neuralgia | 1 | 2.06 |
| Patient 5 | Other Benign Tumor | 19 | 37.96 |
| Patient 6 | Multiple Metastasis | 10 | 18.84 |
| Patient 6 | Multiple Metastasis | 2 | 4.01 |
| Patient 7 | Acoustic Schwannoma | 14 | 27.73 |
| Patient 8 | Single Metastasis | 6 | 11.26 |
| Patient 9 | Acoustic Schwannoma | 12 | 23.76 |
| Patient 10 | Single Metastasis | 9 | 17.29 |
Figure 3Graphical User Interface (a) of the GammaPlan verification tool (GPVT); HTML report (b) of the results obtained from GPVT.
Statistics of the clinical plan dose verification: average over the number of shots, standard deviation, and the range of calculated ratios of GPVT to GammaPlan focus dose.
|
| |||||
|---|---|---|---|---|---|
|
|
|
|
|
|
|
| 1 | 15 | 0.998 | 0.008 | 1.006 | 0.983 |
| 2 | 7 | 1.015 | 0.005 | 1.019 | 1.005 |
| 3 | 18 | 1.002 | 0.008 | 1.018 | 0.991 |
| 4 | 25 | 1.018 | 0.018 | 1.049 | 0.988 |
| 5 | 17 | 0.967 | 0.013 | 0.984 | 0.947 |
| 6 | 12 | 0.990 | 0.009 | 0.999 | 0.969 |
| 7 | 3 | 0.981 | 0.003 | 0.984 | 0.978 |
| 8 | 14 | 1.021 | 0.019 | 1.038 | 0.960 |
| 9 | 30 | 0.978 | 0.014 | 1.021 | 0.955 |
| 10 | 13 | 0.996 | 0.004 | 1.002 | 0.993 |
| 11 | 18 | 1.026 | 0.012 | 1.048 | 1.008 |
| 12 | 6 | 0.973 | 0.003 | 0.977 | 0.968 |
| 13 | 2 | 0.979 | 0.003 | 0.981 | 0.977 |
| 14 | 12 | 0.956 | 0.010 | 0.976 | 0.943 |
| 15 | 11 | 0.997 | 0.008 | 1.008 | 0.983 |
Figure 4Full dose calculation results (patient information omitted): (a)–(c) isodose comparison display for three sample clinical plans; (d) sample dose comparison output.